Duo Oncology is an oncology company reimagining chemotherapy, a foundational treatment for metastatic cancer. Its lead program, DUO-207, consolidates multi-drug chemotherapy regimens into a single, potent prodrug for pancreatic, lung, breast, and other inoperable cancers. DUO-207 is trial-ready, supported by completed IND-enabling studies, orphan designations, and strong preclinical benchmarks versus standard of care.

Duo has secured strategic investment from BeOne Medicines, received multiple SBIR awards, and was selected for the NCI NanoCharacterization Program and the NIH Investor Initiative. Following a favorable FDA pre-IND meeting, Duo is preparing an efficient first-in-human program that begins at Phase 1b and expands into Phase 2 after enrolling the initial nine patients. This capital-efficient strategy is focused on generating early clinical data to support strategic partnering or acquisition within the next three years.